scholarly journals Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-Label Randomized Trial

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Abdul Rehman Arshad
Keyword(s):  
Low Dose ◽  
Controlled Trial ◽  
Lipid Lowering ◽  
Lipid Levels ◽  
Primary And Secondary Prevention ◽  
Percent Reduction ◽  
Open Label ◽  
Randomized Controlled ◽  
To Receive

Background. Treatment of hyperlipidemia is helpful in both primary and secondary prevention of coronary heart disease and stroke.Aim. To compare lipid-lowering efficacy of rosuvastatin with atorvastatin.Methodology. This open-label randomized controlled trial was carried out at 1 Mountain Medical Battalion from September 2012 to August 2013 on patients with type 2 diabetes, hypertension, myocardial infarction, or stroke, meriting treatment with a statin. Those with secondary causes of dyslipidemia were excluded. Blood samples for estimation of serum total cholesterol, triglycerides, HDL-C, and LDL-C were collected after a 12-hour fast. Patients were randomly allocated to receive either atorvastatin 10 mg HS or rosuvastatin 5 mg HS daily. Lipid levels were rechecked after six weeks.Results. Atorvastatin was used in 63 patients and rosuvastatin in 66. There was a greater absolute and percent reduction in serum LDL-C levels with rosuvastatin as compared to atorvastatin (0.96 versus 0.54 mg/dL;P=0.011and 24.34 versus 13.66%;P=0.045), whereas reduction in all other fractions was equal. Myalgias were seen in 5 (7.94%) patients treated with atorvastatin and 8 (12.12%) patients treated with rosuvastatin (P: 0.432).Conclusion. Rosuvastatin produces a greater reduction in serum LDL-C levels and should therefore be preferred over atorvastatin.

scholarly journals Efficacy and Safety of Switching from Low-Dose Statin to High-Intensity Statin for Primary Prevention in Type 2 Diabetes: A Randomized Controlled Trial

2020 ◽  
Vol Volume 13 ◽  
pp. 423-431 ◽  
Author(s):  
Nuntakorn Thongtang ◽  
Jirasak Piyapromdee ◽  
Natthakan Tangkittikasem ◽  
Kittichai Samaithongcharoen ◽  
Nithiwat Srikanchanawat ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Randomized Controlled Trial ◽  
Primary Prevention ◽  
High Intensity ◽  
Low Dose ◽  
Controlled Trial ◽  
Efficacy And Safety ◽  
Randomized Controlled

scholarly journals A three-arm, multicenter, open-label randomized controlled trial of hydroxychloroquine and low-dose prednisone on recurrent spontaneous abortion with undifferentiated connective tissue diseases: Protocol for the immunosuppressant regimens for Living FEtuses (ILIFE) Trial

2020 ◽  
Author(s):  
Shaoying Yang ◽  
Ruoning Ni ◽  
Yikang Lu ◽  
Suli Wang ◽  
Feng Xie ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Connective Tissue ◽  
Spontaneous Abortion ◽  
Pregnancy Outcomes ◽  
Low Dose ◽  
Controlled Trial ◽  
Recurrent Spontaneous Abortion ◽  
Open Label ◽  
Randomized Controlled ◽  
Dose Prednisone

Abstract Background: Undifferentiated connective tissue disease (UCTD) is known to induce adverse pregnancy outcomes, and even recurrent spontaneous abortion (RSA) by placental vascular damage and inflammation activation. Anticoagulation can prevent pregnancy morbidities. However, it is unknown whether the addition of immune suppressant to anticoagulation can prevent spontaneous pregnancy loss in UCTD patients. The purpose of this study is to evaluate the efficacy of hydroxychloroquine (HCQ) and low-dose prednisone on recurrent pregnancy loss for women with UCTD.Methods: The Immunosuppressant for Living Fetuses (ILIFE) Trial is a three-arm, multicenter, open-label randomized controlled trial with the primary objective of comparing hydroxychloroquine combined with low-dose prednisone and anticoagulation with anticoagulation alone in treating UCTD women with recurrent spontaneous abortion. The third arm of using hydroxychloroquine combined with anticoagulant for secondary comparison. A total of 426 eligible patients will be randomly assigned to each of the three arms with a 1:1:1 allocation ratio. The primary outcome is the rate of live births. Secondary outcomes include adverse pregnancy outcomes and progression of UCTD.Discussion: This is the first multi-center, open-label, randomized controlled trial which evaluates the efficacy of immunosuppressant regimens on pregnancy outcomes and UCTD progression. It will provide evidence on whether the immunosuppressant ameliorates the pregnancy prognosis in UCTD patients with RSA and the progression into defined connective tissue disease. Trial registration: ClinicalTrials.gov, NCT03671174. Registered on 14 September 2018. https://www.clinicaltrials.gov/ct2/show/NCT03671174

Sign in / Sign up

Export Citation Format

Share Document